valuing hyact, page-2

Hi Blackk111r.

The bit that stands out for me is this - Nomura however in their detailed report only believe the market size of the global generic irinotecan market will be USD64mn in 2014 but allow the following considerations when formulating a valuation per share

Remember that ACLs version will be a better drug than the current brand leader, and therefore will not be sold as a generic, but it will become the brand leader. This is why the length of progression free survival is so important and why I am excited that the Phase III will take longer than expected due to better than expected results.

If ACL crack this drug and get it on the market, getting an IPO up will be the least of our troubles. Thinking back to market reports last year, there are a lot of companies with deep pockets who are running out of drugs on patent, ACL now has a very exciting drug in phase III showing brilliant results AND have a USA patent till potentially 2023 - now that will get the big boys interested.